{"record_key":"consegna-pharma","identifier":"consegna-pharma","external_key":null,"title":"Consegna Pharma","summary":null,"url":"https://inventions.pitt.edu/startups/consegna-pharma","json_url":"https://inventions.pitt.edu/startups/consegna-pharma.json","object_key":"startups","description":"Consegna Pharma is a Pittsburgh specialty pharmaceutical company that reformulates known, safe drugs into long-acting injectable medications with improved clinical and economic benefits. Its lead candidate, CP216, is a long-acting injectable naloxone designed to reverse an opioid overdose immediately and then release over 12 to 24 hours to prevent renarcotization. [1]: https://app.dealroom.co/companies/consegna_pharma\nThe company was founded in 2017 as a University of Pittsburgh spinout, with Larry Zana as founder, president, and CEO. In April 2022 it acquired Fathom Pharma, adding a pipeline of long-acting pain medicines. [2]: https://lifesciencehistory.com/companies/consegna-pharma/","attributes":[{"key":"website","label":"Website","values":["https://www.consegnapharma.com"]},{"key":"sector","label":"Sector","values":["Therapeutics"]},{"key":"therapeutic_areas","label":"Therapeutic Areas","values":["Mental and Behavioral Health"]},{"key":"therapeutic_indications","label":"Therapeutic Indications","values":["Opioid overdose"]},{"key":"funding_stage","label":"Funding Stage","values":["Seed"]},{"key":"founders","label":"Founders","values":["Larry Zana"]}],"related":[]}